A systematic review of the effectiveness of adalimumab

204
Appendix 10
TABLE 131 Variation 10: TNF inhibitors third (early RA values) (40,000 patients)
Option Cost (£) QSE QALYs QSE
Adal 48,020 155 6.5747 0.0244
Etan 61,120 188 7.0687 0.0257
Adal+MTX 48,339 155 6.6981 0.0242
Etan+MTX 61,228 189 7.1102 0.0257
Infl+MTX 48,105 150 6.6926 0.0243
Base 16,523 37 5.7705 0.0227
Comparison Diff. cost (£) QSE Diff. QALY QSE
Adal – Base 31,497 152 0.8042 0.0249
Etan – Base 44,597 182 1.2982 0.0258
Ad+M – Base 31,816 152 0.9275 0.0246
Et+M – Base 44,705 183 1.3397 0.0258
In+M – Base 31,582 146 0.9220 0.0245
Ad+M – Adal 319 206 0.1233 0.0254
Et+M – Etan 108 244 0.0415 0.0273
Etan – Adal 13,100 227 0.4940 0.0263
Et+M – Ad+M 12,889 227 0.4122 0.0262
Ad+M – In+M 234 202 0.0055 0.0254
Et+M – In+M 13,123 224 0.4177 0.0264
Comparison ICER (£ per QALY) Quasi-CI
Adal – Base 39,200 36,900 to 41,800
Etan – Base 34,400 33,000 to 35,800
Ad+M – Base 34,300 32,500 to 36,300
Et+M – Base 33,400 32,100 to 34,700
In+M – Base 34,300 32,500 to 36,200
Ad+M – Adal Adal+MTX more effective than Adal alone; diff. cost not significant
Et+M – Etan Comparison is inconclusive
Etan – Adal 26,500 23,800 to 29,900
Et+M – Ad+M 31,300 27,600 to 36,000
Ad+M – In+M Comparison is inconclusive
Et+M – In+M 31,400 27,800 to 36,200
TABLE 132 Variation 10: TNF inhibitors third (late RA values) (200,000 patients)
Option Cost (£) QSE QALYs QSE
Adal 47,421 69 5.8207 0.0108
Etan 60,281 84 6.4823 0.0113
Adal+MTX 47,890 69 6.0967 0.0107
Etan+MTX 60,167 84 6.4569 0.0114
Infl+MTX 47,275 66 5.8505 0.0108
Base 16,478 17 5.7252 0.0101
Comparison Diff. cost (£) QSE Diff. QALY QSE
Adal – Base 30,943 67 0.0955 0.0106
Etan – Base 43,803 81 0.7571 0.0112
Ad+M – Base 31,412 68 0.3714 0.0107
Et+M – Base 43,690 81 0.7317 0.0113
In+M – Base 30,797 64 0.1253 0.0107
Ad+M – Adal 469 91 0.2760 0.0107
Etan – Et+M 113 108 0.0253 0.0117
Etan – Adal 12,861 100 0.6616 0.0111
Et+M – Ad+M 12,277 100 0.3603 0.0113
Ad+M – In+M 615 89 0.2461 0.0107
Et+M – In+M 12,893 98 0.6064 0.0113
continued